CNS Safety pharmacology: why?

It is important to evaluate the CNS Safety of drugs under development early on during the drug discovery process to avoid surprises later on during the clinical phase. CNS Safety pharmacology aims at evaluating potential side effects on cognitive functions of drugs entering the Central Nervous System.

CNS Safety assays

in vitro assays

  • Neuroservice, our member expert in cell and slice electrophysiology, proposes
    • Safety tests on rodent slices
    • Safety tests on human iPSC-derived neurons
  • AnaBios, our CNS CRO expert in human tissue samples & services for CNS drug discovery, provides:
    • Safety tests on human sensory neurons

in vivo assays

  • CILcare, our CRO expert in hearing disorders, proposes different models of ototoxicity to screen for potentially ototoxic compounds (in vitro & in vivo)

 

Bruno BUISSON, PhD
Co-Founder, President & CSO
NEUROSERVICES-ALLIANCE
& NEUROSERVICE
Bob PETROSKI, PhD
Scientific liaison
NEUROSERVICES-ALLIANCE
Andre GHETTI, PhD
CEO
ANABIOS
Najah ABI-GERGES, PhD
VP of R&D
ANABIOS
Paul E. MILLER, PhD
CBO
ANABIOS
Celia BELLINE, MSc
CEO, Hearing Disorders expert
CILCARE
Gaƫlle NAERT, PhD
COO, Hearing Disorders expert
CILCARE
Marie-Pierre PASDELOU, Pharm.D
CDO, Hearing Disorders expert
CILCARE
Sylvie PUCHEU, PhD
CSO, Hearing Disorders expert
CILCARE